Developing a Pipeline of Therapeutic Antibodies Targeting oxMIF

We discovered it, we named it, we are drugging it.

OncoOne is generating novel biotherapeutics targeting oxMIF for the treatment of solid tumors and chronic inflammatory diseases. In addition, OncoOne launched its PreTarg-it® platform to broaden its portfolio to other targets and cancer indications.

Our Pipeline: Therapeutic Antibodies targeting oxMIF